Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A dose-defining study of sumatriptan suppositories in the acute treatment of migraine
Autore:
Bertin, L; Brion, N; Farkkila, M; Gobel, H; Wessely, P;
Indirizzi:
Glaxo Wellcome Inc, Greenford, Middx, England Glaxo Wellcome Inc Greenford Middx England nc, Greenford, Middx, England Glaxo Wellcome Inc, Versailles, France Glaxo Wellcome Inc Versailles France o Wellcome Inc, Versailles, France Glaxo Wellcome Inc, Helsinki, Finland Glaxo Wellcome Inc Helsinki Finland axo Wellcome Inc, Helsinki, Finland Glaxo Wellcome Inc, Kiel, Germany Glaxo Wellcome Inc Kiel GermanyGlaxo Wellcome Inc, Kiel, Germany Glaxo Wellcome Inc, Vienna, Austria Glaxo Wellcome Inc Vienna AustriaGlaxo Wellcome Inc, Vienna, Austria
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 8, volume: 53, anno: 1999,
pagine: 593 -
SICI:
1368-5031(199912)53:8<593:ADSOSS>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
14
Recensione:
Indirizzi per estratti:
Indirizzo: Bertin, L Glaxo Wellcome Inc, 5 Moore Dr, Res Triangle Pk, NC 27709 USA Glaxo Wellcome Inc 5 Moore Dr Res Triangle Pk NC USA 27709 9 USA
Citazione:
L. Bertin et al., "A dose-defining study of sumatriptan suppositories in the acute treatment of migraine", INT J CL PR, 53(8), 1999, pp. 593

Abstract

In this dose-ranging, randomised, multinational, multicentre, double-blind, placebo-controlled, parallel group study, 431 patients treated a single migraine attack with study medication: sumatriptan suppository 6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, or placebo. Patients were treated in the clinic with a single dose in suppository form. All doses of sumatriptan, except 6 mg,were significantly better than placebo (p<0.004) and achieved similar rates of headache relief within two hours of dosing. The highest response rate was in the 25 mg group (72%) compared with placebo (37%) (p<0.001). Fewer patients required rescue medication in the active groups (1% 100 mg to 13% 6mg) compared with placebo (17%), and more patients were able to work and function normally two hours after dosing (41%, 100 mg; 20%, placebo). The overall incidence of adverse events was similar in the placebo, 6 mg and 12.5mg groups (14-17%) but higher in the 25 mg, 50 mg and 100 mg groups (25%, 32% and 29% respectively). Analysis of plasma sumatriptan levels indicated rapid rectal absorption for all doses (median t(max)=1.0 hr). It is concluded that sumatriptan, in doses above 6 mg, is an effective and well tolerated treatment for acute migraine. From this study doses of 12.5 mg and 25 mg sumatriptan were-identified as having the best efficacy/safey profile and were evaluated further.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:21:58